A Wilms' tumor gene WT1 is expressed at high levels not only in most types of
leukemia but also in various types of solid
tumors, including lung and
breast cancer.
WT1 protein has been reported to serve as a target
antigen for
tumor-specific
immunotherapy both in vitro in human systems and in vivo in murine models. We have shown that mice immunized with WT1
peptide or WT1
cDNA could reject a challenge from WT1-expressing
tumor cells (a "prophylactic" model). However, it was not examined whether WT1
peptide vaccination had the potency to reject
tumor cells in a "therapeutic" setting. In the present study, we demonstrated for the first time that WT1
peptide vaccination combined with Mycobacterium bovis bacillus Calmette-Guérin
cell wall skeleton (BCG-CWS) was more effective for eradication of WT1-expressing
tumor cells that had been implanted into mice before vaccination (a "therapeutic" model) compared with WT1
peptide vaccination alone. An
intradermal injection of BCG-CWS into mice, followed by that of WT1
peptide at the same site on the next day, generated WT1-specific cytotoxic T lymphocytes (CTLs) and led to rejection of WT1-expressing
leukemia or
lung cancer cells. These results showed that BCG-CWS, which was well known to enhance innate immunity, could enhance WT1-specific immune responses (acquired immunity) in combination with WT1
peptide vaccination. Therefore, WT1
peptide vaccination combined with BCG-CWS may be applied to
cancer immunotherapy in clinical settings.